HCV ADVOCATE WEEKLY NEWS REVIEW

[Guest guest]

HCV ADVOCATE WEEKLY NEWS REVIEW

Week Ending: July 31, 2010

This Issue:

Can-Fite Reports CF102 Success against Hepatitis Effects of Milk Thistle Extract on the Hepatitis C Virus Lifecycle Hepatitis C Rate May Be Down in the U.S.: Study 13 More Hep C Cases Linked to Anaesthetist ‘More Targeted’ Treatment Key to Helping Crack Users: Study Novel Program Rescues Skid Row's Most Vulnerable Health, Community Leaders in San Francisco Campaign Against Hepatitis B No End in Sight for Adult Hepatitis B Vaccine Shortage Bill That Allows Over-the-Counter Sales of Syringes Set to Expire LabCorp Gains Rights to Merck & Co.’s IL-28B Polymorphism IP for HCV Therapy Predictive Test Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-938 in Patients with Chronic Hepatitis C At-Risk Groups Urged to Get Tested for Hepatitis B Hepatitis C Re-Treatment Offers Hope if Initial One Fails UPDATE 1-Vertex Has Begun Telaprevir FDA Application Miami VA: Remaining Veterans Notified of Disease Exposure Greater Risk of Diabetes Found in Hepatitis C Patients ANA598 Demonstrates SVR12 in 100% of First Group of HCV Patients Randomized to Stop All Treatment at Week 24 More Catalysts Ahead for Vertex Pharmaceuticals VA: 3 Positive Tests of Vets at St. Louis Clinic Genetic Diversity of Hepatitis C Virus Predicts Recurrent Disease after Liver Transplantation Victim of Blood Products Sues for Hep C Relief

http://www.hcvadvocate.org/news/newsRev/2010/NewsRev-372.html